Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome

10.1634/theoncologist.12-9-1084

10.2217/imt.15.108

10.1182/blood-2013-02-485623

10.1097/CCM.0000000000002053

10.1634/theoncologist.2018-0028

10.1056/NEJMoa1709866

10.1158/1078-0432.CCR-07-0674

10.1056/NEJMoa1407222

10.1182/blood-2018-99-112599

10.1056/NEJMoa1709919

10.1182/blood-2017-06-793141

10.1126/scitranslmed.3008226

10.1038/nm.4441

10.1182/blood-2011-10-387969

10.1158/1538-7445.AM2018-LB-108

10.1200/JCO.2016.67.3301

10.1056/NEJMoa1609783

10.1182/blood-2016-04-703751

10.1002/pbc.26642

10.1182/blood.V94.7.2217.419k02_2217_2224

10.1182/blood-2017-06-786129

10.1182/blood-2014-05-552729

10.1158/2326-6066.CIR-13-0006

10.1097/PPO.0000000000000035

10.1158/2159-8290.CD-16-0040

10.1182/blood.V120.21.2135.2135

10.1016/j.jpeds.2011.11.046

10.1056/NEJMoa1707447

10.1016/j.immuni.2016.01.021

10.1200/JCO.2018.36.15_suppl.3041

10.1097/CJI.0000000000000241

10.1158/2326-6066.CIR-17-0211

10.1158/2159-8290.CD-17-1319

10.1016/j.bbmt.2018.12.758

10.1158/2159-8290.CD-17-0698

10.1200/JCO.2016.71.3024

Gilbert MJ, 2017, Presented at Society for Immunotherapy of Cancer, National Harbor

10.1158/2159-8290.CD-17-1084

10.1038/nrd.2018.45

10.1038/ni.3632

10.1177/1078155217745144

10.1016/j.bbmt.2015.11.800

10.1016/j.bbmt.2016.06.010

10.1182/blood.V128.22.652.652

National Center for Biotechnology Information. PubChem Substance Database; SID=354702205, https://pubchem.ncbi.nlm.nih.gov/substance/354702205

10.1016/j.nbd.2016.02.007

10.1038/nrclinonc.2017.148

10.1038/s41591-018-0036-4

10.1182/blood-2018-10-881722

Gallenga CE, 2019, J Biol Regul Homeost Agents, 33, 1